Pancreatic Cancer Research

ResearcherIRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'OrsolaActive in the last 2 years

Elio Jovine

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1514-7772; OpenAlex author ID A5085679623. Sources: OpenAlex.

Their work

Papers
20 (first author 0, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
37
Papers, trials and grants by year

2012: 1 paper · 2013: 2 papers · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: 3 papers · 2019: 2 papers · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 2 papers · 2024: 2 papers · 2025: 1 paper · 2026: 2 papers

Papers 20

  1. Multicenter IGoMIPS Registry-based analysis of robotic versus laparoscopic approach to left pancreatectomy for pancreatic cancer. Co-author DOI 10.1007/s13304-026-02831-3↗
  2. Focus on the Interactive Cooperation Among Mechanotransduction and Biochemical Processes in Pancreatic Ductal Adenocarcinoma Development and Possible Adjuvant … Co-author DOI 10.3390/cancers18121932↗
  3. Pancreatic cancer and long survivors: a survey of Italian society of oncological surgery (SICO). Co-author DOI 10.1007/s13304-024-02039-3↗
  4. The pan - COVID - AGICT study. The impact of COVID-19 pandemic on surgically treated pancreatic cancer patients. A multicentric Italian study. Co-author DOI 10.1016/j.suronc.2024.102081↗
  5. REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006248↗
  6. Regret affects the choice between neoadjuvant therapy and upfront surgery for potentially resectable pancreatic cancer. Co-author DOI 10.1016/j.surg.2023.01.016↗
  7. The Importance of Reading the Skin: Cutaneous Metastases of Pancreatic Cancer, a Systematic Review. Co-author DOI 10.3390/jcm13010104↗
  8. Molecular Characterization of Pancreatic Ductal Adenocarcinoma Using a Next-Generation Sequencing Custom-Designed Multigene Panel. Co-author DOI 10.3390/diagnostics12051058↗
  9. Periostin, tenascin, osteopontin isoforms in long- and non-long survival patients with pancreatic cancer: a pilot study. Co-author DOI 10.1007/s11033-020-05763-2↗
  10. The impact of extent of pancreatic and venous resection on survival for patients with pancreatic cancer. Last author DOI 10.1016/j.hbpd.2019.06.004↗
  11. Corrigendum to "Evolution of pancreatectomy with en bloc venous resection for pancreatic cancer in Italy. Retrospective cohort study on 425 cases in 10 pancrea… Co-author DOI 10.1016/j.ijsu.2019.05.015↗
  12. Evolution of pancreatectomy with en bloc venous resection for pancreatic cancer in Italy. Retrospective cohort study on 425 cases in 10 pancreatic referral uni… Co-author DOI 10.1016/j.ijsu.2018.05.025↗
  13. Matricellular proteins and survival in patients with pancreatic cancer: A systematic review. Co-author DOI 10.1016/j.pan.2017.11.001↗
  14. Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4. Co-author DOI 10.3233/cbm-170464↗
  15. Prognostic role of nodal ratio, LODDS, pN in patients with pancreatic cancer with venous involvement. Co-author DOI 10.1186/s12893-017-0311-1↗
  16. Pancreatectomy with Mesenteric and Portal Vein Resection for Borderline Resectable Pancreatic Cancer: Multicenter Study of 406 Patients. Co-author DOI 10.1245/s10434-016-5123-5↗
  17. Surgery for isolated liver metastases from pancreatic cancer. Last author DOI 10.1007/s13304-015-0283-6↗
  18. Association between hepatitis B or hepatitis C virus infection and risk of pancreatic adenocarcinoma development: a systematic review and meta-analysis. Last author DOI 10.1016/j.pan.2013.01.005↗
  19. HBV- and HCV-related infections and risk of pancreatic cancer. Last author DOI 10.6092/1590-8577/1948↗
  20. Hepatitis B and C virus infections as possible risk factor for pancreatic adenocarcinoma. Last author DOI 10.1016/j.mehy.2012.08.008↗

Closest collaborators

The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sirio Fiorino · 8 shared papers, 2012–2026 · strength 0.71
  2. Dario de Biase · 5 shared papers, 2018–2026 · strength 0.60
  3. Michele Masetti · 8 shared papers, 2012–2022 · strength 0.54
  4. Giovanni Tallini · 3 shared papers, 2018–2022 · strength 0.28
  5. Maddalena Zippi · 1 shared paper, 2026 · strength 0.27
  6. Niccolò Petrucciani · 4 shared papers, 2016–2019 · strength 0.26
  7. Giuseppe R. Nigri · 4 shared papers, 2016–2019 · strength 0.26
  8. Francesco Minni · 4 shared papers, 2016–2019 · strength 0.26
  9. Niccolò Napoli · 4 shared papers, 2016–2019 · strength 0.26
  10. Giovanni Ramacciato · 4 shared papers, 2016–2019 · strength 0.26
  11. Ugo Boggi · 4 shared papers, 2016–2019 · strength 0.26
  12. Antonio Daniele Pinna · 4 shared papers, 2016–2019 · strength 0.26
  13. Michela Visani · 3 shared papers, 2018–2020 · strength 0.21
  14. Carlo Fabbri · 3 shared papers, 2018–2020 · strength 0.21
  15. Giampaolo Perri · 1 shared paper, 2023 · strength 0.17
  16. Umberto Cillo · 1 shared paper, 2023 · strength 0.17
  17. Fortunato Cassalia · 1 shared paper, 2023 · strength 0.17
  18. Giovanni Marchegiani · 1 shared paper, 2023 · strength 0.17
  19. Lapo Bencini · 1 shared paper, 2025 · strength 0.16
  20. Giovanni Luigi Capretti · 1 shared paper, 2025 · strength 0.16
  21. Riccardo Casadei · 1 shared paper, 2025 · strength 0.16
  22. Claudio Ricci · 1 shared paper, 2025 · strength 0.16
  23. Carlo Ingaldi · 1 shared paper, 2025 · strength 0.16
  24. Riccardo Memeo · 1 shared paper, 2025 · strength 0.16
  25. Domenico Tamburrino · 1 shared paper, 2025 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.